Ratio Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-07-31.
Ratio Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on July 31, 2026. The filing reports $70M sold. Its industry group is Pharmaceuticals. It names John Hoppin (Executive Officer, Director), John Babich (Director), Marc Becker (Executive Officer) (SEC Form D, July 31, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Ratio Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-07-31 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Ratio Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Ratio Therapeutics, Inc., from the filings we hold.
Pharmaceuticals raises by companies based in Massachusetts, filed within 90 days of this one, largest first.
Get an email when Ratio Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Ratio Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Ratio Therapeutics, Inc. →Get the full cited report on Ratio Therapeutics, Inc.
What the filing shows about Ratio Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ratio Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Ratio Therapeutics, Inc.'s address as One Design Center Place, Suite 19-601, Boston, MA 02210.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Ratio Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Ratio Therapeutics, Inc. See pricing
Ratio Therapeutics, Inc. is a registered filer with the SEC (CIK 2004792) and has filed since 2023-12-21. 2 filings are on record, the latest on 2026-07-31.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Ratio Therapeutics, Inc.'s Form D of 2026-07-31 names John Hoppin, John Babich, Marc Becker and 6 more as its officers, directors or promoters.
Its new offerings report $120.67M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $70M, on the same scale — one filing against the whole group's total, so it sits low by construction.
John Hoppin is named as Executive Officer and Director on the Form D that Ratio Therapeutics, Inc. filed with the SEC on 31 July 2026, one of 9 people that filing names.
John Babich is named as Director on the Form D that Ratio Therapeutics, Inc. filed with the SEC on 31 July 2026, one of 9 people that filing names.
Marc Becker is named as Executive Officer on the Form D that Ratio Therapeutics, Inc. filed with the SEC on 31 July 2026, one of 9 people that filing names.
Scott MacDonald is named as Executive Officer on the Form D that Ratio Therapeutics, Inc. filed with the SEC on 31 July 2026, one of 9 people that filing names.
William Cowan is named as Director on the Form D that Ratio Therapeutics, Inc. filed with the SEC on 31 July 2026, one of 9 people that filing names.
Susan Whoriskey is named as Director on the Form D that Ratio Therapeutics, Inc. filed with the SEC on 31 July 2026, one of 9 people that filing names.
Albert Holman is named as Director on the Form D that Ratio Therapeutics, Inc. filed with the SEC on 31 July 2026, one of 9 people that filing names.
Allan Green is named as Director on the Form D that Ratio Therapeutics, Inc. filed with the SEC on 31 July 2026, one of 9 people that filing names.
Brandon Ingersoll is named as Director on the Form D that Ratio Therapeutics, Inc. filed with the SEC on 31 July 2026, one of 9 people that filing names.
9 people named on the filing — 3 holding an executive role and 6 as directors only.
Named as of the 2026-07-31 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Ratio Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Ratio Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ratio Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Ratio Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Ratio Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Ratio Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Boston raises, week of 2026-07-27 · Pharmaceuticals raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/ratio-therapeutics-inc-form-d-26000001